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The effectiveness of different breast cancer follow-up procedures to decrease breast cancer mortality are still an
object of debate, even if intensive follow-up by imaging modalities is not recommended by international guidelines
since 1997. We conducted a systematic review of surveillance procedures utilized, in the last ten years, in phase III
randomized trials (RCTs) of adjuvant treatments in early stage breast cancer with disease free survival as primary
endpoint of the study, in order to verify if a similar variance exists in the scientific world. Follow-up modalities were
reported in 66 RCTs, and among them, minimal and intensive approaches were equally represented, each being
followed by 33 (50%) trials. The minimal surveillance regimen is preferred by international and North American RCTs
(P = 0.001) and by trials involving more than one country (P = 0.004), with no relationship with the number of
participating centers (P = 0.173), with pharmaceutical industry sponsorship (P = 0.80) and with trials enrolling > 1000
patients (P = 0.14). At multivariate regression analysis, only geographic location of the trial was predictive for a
distinct follow-up methodology (P = 0.008): Western European (P = 0.004) and East Asian studies (P = 0.010) use
intensive follow-up procedures with a significantly higher frequency than international RCTs, while no differences
have been detected between North American and international RCTs. Stratifying the studies according to the date
of beginning of patients enrollment, before or after 1998, in more recent RCTs the minimal approach is more
frequently followed by international and North American RCTs (P = 0.01), by trials involving more than one country
(P = 0.01) and with more than 50 participating centers (P = 0.02). It would be highly desirable that in the near future
breast cancer follow-up procedures will be homogeneous in RCTs and everyday clinical settings.
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In the last years, a substantial increase in the number of
women surviving breast cancer [1], the most frequent
female cancer in the world [2-5], has been reported. This
leads to the necessity to focus on breast cancer follow-
up procedures for the high relevance they have for both
patients and professional personnel [6]. The primary aim
of routine post-operative surveillance after early stage
breast cancer surgery, referred to as ‘follow-up’, is to en-
hance survival, psychosocial and physical well-being of
patients. The effectiveness of different breast cancer* Correspondence: natoli@unich.it
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stated.follow-up procedures for early detection of metastatic dis-
ease is an old issue, starting in the 1980s [7-10]. In the
1990s, evidences from phase III randomized trials (RCTs)
demonstrated that intensive follow-up procedures do not
improve outcome or quality of life when compared to pa-
tients’ educations about symptoms referral and regular
physical examinations [11-18]. Nowadays, there is a gen-
eral agreement on the utility of yearly mammography for
detecting local recurrences and/or second primary cancers
while intensive follow-up practices by imaging techniques
(i.e. chest radiograph, bone scan and liver sonography) are
not recommended by current international guidelines
[19,20]. Nevertheless, the appropriateness of screening
tests to be used as well as the frequency of follow-up pro-
cedures and the optimal follow-up duration are still objectl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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sive surveillance and in the long-term follow-up period in
everyday clinical practice [6,25-28].
Based on these premises, we conducted a systematic
review of the surveillance procedures utilized in phase
III RCTs of adjuvant treatments in early stage breast
cancer in order to asses if a similar variance exists in the
scientific world.
Methods
Literature search and eligibility criteria
We searched PubMed (PubMed, available at URL:
www.ncbi.nlm.nih.gov/pubmed) from January 1, 2002
to December 31, 2012 for phase III RCTs of early breast
cancer medical adjuvant therapies with disease free sur-
vival (DFS) as primary endpoint of the study [29]. We
selected only full text publications (not abstracts), written in
English-language. Trials on neoadjuvant therapies, neoadju-
vant followed by adjuvant therapies, adjuvant bisphospho-
nates alone, non medical treatments, radiation therapies,
adjuvant chemotherapy for loco-regional relapses and non-
phase III trials were excluded. When multiple publications
of the same RCT were identified, the first publication was
selected. We used as keywords: breast cancer adjuvant ther-
apy, clinical trial, phase III, phase 3 and randomized.
Data extraction
Information extracted from each trial included: date of be-
ginning of patients enrollment, geographic location, number
of participating countries, sponsorship by pharmaceutical
companies, number of participating centers, number of en-
rolled patients, follow-up description (modalities, frequency
and duration). Follow-up was classified as minimal when
only history/physical examination and/or automated blood
chemistry studies, and intensive when chest radiographs ±
bone scan ± liver sonography ± tumor markers were in-
cluded. Screening and data extraction were performed inde-
pendently by two investigators.
Statistics
Descriptive statistics were used to report relevant study
information. The associations between variables and
follow-up data were tested by the Pearson’s chi-square
test or Fisher’s exact test, as appropriate. All p values are
reported as 2-sided and p values less than 0.05 denotes
statistically significant association. A multiple corres-
pondence analysis (MCA), an exploratory multivariate
statistical technique, was used to analyze possible rela-
tionships among all variables and identify specific pro-
files [30]. In the MCA, associations between variables
are displayed graphically as maps, and their position in
the graphic is exclusively informative. The prediction of
follow-up procedures was evaluated using a stepwise
multivariate logistic regression. The cut-off p value forinclusion or exclusion in the model was set at 0.10 and
0.15, respectively. The Odds Ratio (OR) and the 95%
confidence intervals (95% CI) were estimated for each
variable. The SPSS software (SPSS version 19.0, SPSS
Inc., Chicago, Illinois, USA) was used for all statistical
evaluations.
Results
Of 441 potentially relevant abstracts identified, 98 papers
met full inclusion criteria: follow-up modalities were re-
ported in 66 RCTs [31-95] while no information was
given in the remaining 32 [96-127]. Two different trials,
the ABCSG trial 8 and ARNO 95 trial, are reported in
the same paper by Jakesz et al. [58]. The flowchart of
search strategy is shown in Figure 1.
As shown in Table 1, there is a trend towards more
frequently describing surveillance procedures in papers
from international, West European or East Asian (Japan,
Vietnam and China) RCTs than in those from North
American (USA and Canada) RCTs (P = 0.06); no rela-
tionship has been found between other variables taken
into account and the availability of follow-up data.
Among the 66 papers describing follow-up method-
ology, minimal and intensive approaches were equally
represented, each being followed by 33 (50%) trials. Only
6 papers report the use of tumor markers measurement
(carcinoembryonic antigen and carbohydrate antigen
15–3) during follow-up [46,48,57,75,82,88] and none in-
cludes the use of computed tomography scans, positron
emission tomography scanning and magnetic resonance
imaging.
Table 2 shows that the minimal surveillance regimen
is preferred by international and North American
RCTs (P = 0.001) and by trials involving more than one
country (P = 0.004), while there is no relationship with
the number of participating centers (P = 0.173), the
pharmaceutical industry sponsorship (P = 0.80), trials
enrolling > 1000 patients (P = 0.14). Breast cancer follow-
up guidelines, recommending the minimal approach, were
published by the American Society of Clinical Oncology
in 1997 [128]. Interestingly, no differences in follow-up
modalities have been detected in RCTs enrolling patients
before and after 1998 (P = 0.58). Stratifying data according
to the date of beginning of patients enrollment (i.e. before
or after 1998), even if numbers are small, in more recent
studies there is a higher use of the minimal approach by
international and North American RCTs (P = 0.01) and by
trials involving more than one country (P = 0.01), and
more than 50 participating centers (P = 0.02), with a trend
toward statistical significance for trials enrolling > 1000
patients (P = 0.06) (Table 3).
The graphical map of MCA (Figure 2) shows that in-
tensive follow-up procedures cluster with Western
European and East Asian studies, studies with less than
Figure 1 Flowchart of study selection.
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tients, and with patients enrollment beginning before
1998, while the minimal approach clusters with RCTs
enrolling more than 1000 patients and beginning enroll-
ment after 1998 (Figure 2). At multivariate regression ana-
lysis, only geographic location of the trial was predictive
for a distinct follow-up methodology (P = 0.008). In par-
ticular, setting as a reference the international studies,
Western European (P = 0.004) and East Asian studies
(P = 0.010) use intensive follow-up procedures with a
significantly higher frequency than international RCTs,
while no differences are detected between North
American and international RCTs.
For each follow-up approach, the frequency at which
the different exams are performed is highly variable,
ranging from 1 to 4 times/year for history and/or phys-
ical examinations, and from 1 to 3 times/year for im-
aging modalities, as shown in Table 4. Almost all RCTs
showed the highest number of evaluations/year in the
first 1–2 years of follow-up; 5-year follow-up and annu-
ally thereafter was chosen by almost all studies, with
the following exceptions: two studies interrupted all im-
aging modalities at the 3rd year [83,84]; one studydiscontinued chest radiographs and bone scan at the
4th year [46] and one study ended chest radiographs at
the 3rd year [66].Discussion
The results of our systematic review demonstrates that
among phase III RCTs of adjuvant therapies for early
stage breast cancer, minimal and intensive follow-up ap-
proaches are equally used. However, it should be noted
that not all the papers, mainly from North America, re-
port the modalities of follow-up [91-121], even if we se-
lected RCTs with primary endpoint represented by DFS,
which can be affected by the surveillance methodologies
applied. Possible explanations could be that i) the au-
thors and referees do not think this is a relevant issue or
ii) a follow-up according to established guidelines was
applied, thus making it unnecessary to specify. The sec-
ond hypothesis may be more likely, since the minimalist
follow-up suggested by international guidelines is more
frequently followed by North American while intensive
follow-up is preferred by Western European and East
Asian trialists.
Table 1 Description of follow-up procedures in RCTs
Follow-up data P value
Yes NO
No. (%) No. (%)
Geographic location
International 13 (68) 6 (32) 0.06
North America (USA and Canada) 10 (48) 11 (52)
Western Europe 38 (79) 10 (21)
East Asia (Japan, Vietnam, China) 5 (56) 4 (44)
Number of participating countries
1 country+ 43 (66) 22 (34) 0.49
> 1 country 23 (74) 8 (26)
Number of participating centers
≤ 50 29 (81) 7 (19) 0.75
> 50 17 (77) 5 (23)
Industry sponsorship
Yes 37 (75) 12 (25) 0.64
No 29 (69) 13 (31)
Number of enrolled patients
≤ 1000 patients 34 (76) 11 (24) 0.14
> 1000 patients 32 (62) 20 (38)
Legends: RCTs = randomized clinical trials.





No. (%) No. (%)
Geographic location
International 12 (92) 1(8) 0.001
North America (USA and Canada) 7 (70) 3 (30)
Western Europe 13 (34) 25 (66)
East Asia (Japan, Vietnam, China) 1 (20) 4 (80)
Number of participating countries
1 country 16 (37) 27 (63) 0.004
> 1 country 17 (74) 6 (26)
Number of participating centers
≤ 50 11 (38) 18 (62) 0.173
> 50 10 (59) 7 (42)
Industry sponsorship
Yes 18 (49) 19 (51) 0.80
No 15 (52) 14 (48)
Number of enrolled patients
≤ 1000 patients 14 (41) 20 (58) 0.14
> 1000 patients 19 (59) 13 (41)
Date of beginning of patients
enrollment
From 1981 to 1997 23 (48) 25 (52) 0.58
From 1998 to 2002 10 (56) 8 (44)
Legends: RCTs = randomized clinical trials.
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strategies of follow-up is not dictated by the necessity of
costs containment as it has been suggested [129-131],
since no relationship with industrial sponsorships,
number of participating centers and number of enrolled
patients has been found. It seems more likely that the
intensive surveillance methodology in RCTs follows
Western European and East Asian cultural attitudes of
scientists and medical oncologists towards the care of
breast cancer patients [132]. In this respect, it has re-
cently been reported that many European and East
Asian breast cancer patients receive more intensive
follow-up care than recommended by the current
guideline [6,25,26,133,134] even if, at a lesser extent,
this has been also reported for American and Canadian
patients [27,28].
The frequency of follow-up is higher in the first 2–
3 years after surgery and tends to decrease thereafter.
Almost all RCTs, except few studies [46,83,84], continue
programmed controls at least 5 years after treatment, in-
dependently from the chosen follow-up methodology.
These issues are still object of debate [135], since neither
the optimum frequency nor duration of follow-up has
been clearly defined [23,136,137].
Results from two Italian phase III RCTs, both published
in 1994 [11,12] and several retrospective studies [138-141]
demonstrated that intensive follow-up strategies including
chest radiography, bone scan, liver ultrasound and tumormarkers measurements do not improve survival as com-
pared to history taking, physical examinations and annual
mammography. On the basis of these data, the American
Society of Clinical Oncology published in 1997 and peri-
odically updated thereafter [19,128,142] breast cancer
follow-up guidelines recommending a minimal approach.
We found no increase in the use of minimalist follow-up
among RCTs beginning to enroll patients one year after
published guidelines (i.e. 1998). However, more recently
the minimal approach is being preferred by most inter-
national and North American RCTs, and bigger trials,
such as those involving more than one country and more
than 50 participating centers. It is relevant to point up that
the use of the intensive follow-up is still present in almost
45% of new generation RCTs.
A possible limit of our study may be represented by
the choice of studies written in English, although the
vast majority of RCTs are currently published in this
language and in scientific journal indexed in PubMed.
In addition, it should be underlined that it is likely the
statistic analysis could be not completely reliable, con-
sidering that in some of the subcategories considered in
the study, the number of eligible RCTs is low.
Table 3 Follow-up methodologies in RCTs according to the date of beginning of patients enrollment
Date of beginning of patients enrollment
Before 1998 After 1998
Follow-up approach Follow-up approach
Minimal Intensive Minimal Intensive
No. (%) No. (%) P value No. (%) No. (%) P value
Geographic location
International 7 (87) 1 (13) 5 (100) - 0.01
North America (USA and Canada) 3 (60) 2 (40) 4 (80) 1 (20)
Western Europe 12 (37) 20 (63) 1 (16) 5 (83)
East Asia (Japan, Vietnam, China) 1 (33) 2 (67) 0.07 - 2 (100)
Number of participating countries
1 country 13 (39) 20 (60) 3 (30) 7 (70) 0.01
> 1 country 10 (66) 5 (33) 0.08 7 (87) 1 (87)
Number of participating centers
≤ 50 11 (46) 13 (54) - 5 (100.0) 0.02
> 50 6 (54) 5 (46) 0.63 4 (67) 2 (33)
Industry sponsorship
Yes 9 (41) 13 (59) 9 (60) 6 (40) 0.40
No 14 (54) 12 (46) 0.37 1 (33) 2 (67)
Number of enrolled patients
≤ 1000 patients 13 (45) 16 (55) 1 (20.0) 4 (80.0) 0.06
> 1000 patients 10 (53) 9 (47) 0.60 9 (69) 4 (31)
Figure 2 Multiple correspondence analysis of possible relationships among all variables.
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Table 4 Frequency of different exams from year 1 to 5 of follow-up





















times/year times/year times/year times/year times/year times/year times/year times/year times/year times/year
History/physical examination 46 RCTs Median 4.0 4.0 2.0 4.0 2.0 2.0 2.0 2.0 2.0 2.0
Lower-Higher limit 1.0-4.0 1.0-4.0 2.0-4.o 1.0-4.0 1.0-2.0 1.0-4.0 2.0 1.0-4.0 1.0-2.0 1.0-4.0
Physical examination 18 RCTs Median 3.0 3.5 2.5 3.0 2.0 2.5 2.0 2.0 2.0 2.0
Lower-Higher limit 1.0-4.0 3.0-4.0 1.0-4.0 2.0-4.0 2.0-4.0 3.0-4.0 1.0-4.0 1.0-3.0 1.0-4.0 1.0-3.0
Chest radiograph 33 RCTs Median 1.0 1.0 1.0 1.0 1.0
Lower-Higher limit 1.0-3.0 1.0-3.0 1.0-3.0 1.0-2.0 1.0-2.0
Bone scan 19 RCTs Median 1.0 1.0 1.0 1.0 1.0
Lower-Higher limit 1.0-3.0 1.0-3.0 1.0-3.0 1.0-3.0 1.0-2.0
Liver sonography 24 RCTs Median 1.0 1.0 1.0 1.0 1.0
Lower-Higher limit 1.0-3.0 1.0-3.0 1.0-3.0 1.0-2.0 1.0-2.0
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Current breast cancer follow-up guidelines, which are
based on RCTs, suggest a minimal follow-up approach
for surveillance of early breast cancer patients, but this
suggestion is not widely applied neither in phase III
RCTs of adjuvant treatments nor in real world clinical
practice. Whether the minimal follow-up approach will
still be the recommended option in the future, is to be
confirmed. In fact, more effective and sophisticated diag-
nostic procedures may be useful to point out severe
long-term side effects of new molecularly targeted
agents as well as an early detection of oligometastatic
disease might be suitable for cure with newer thera-
peutic strategies, as it has been suggested for other neo-
plasms [143]. Finally, it would be highly desirable that in
the near future the follow-up procedures will be homo-
geneous in RCTs and everyday clinical settings.
Abbreviations
DFS: Disease free survival; MCA: Multiple correspondence analysis; OR: Odds
ratio; RCTs: Randomized clinical trials.
Competing interests
The authors have no potential conflicts of interest to declare.
Authors’ contributions
IS supervised the data collection, performed the statistical analyses and
revised the manuscript; AG, MDT and GC performed literature search and
data extraction; NT and TG wrote the manuscript; PV and SI critically revised
the manuscript; CN conceived the study and critically revised the
manuscript. All authors read and approved the final manuscript.
Acknowledgments
Supported by the Consorzio Interuniversitario Nazionale per Bio-Oncologia
(CINBO). The authors are grateful to Mrs. Camille St. Pierre for careful
reviewing of the manuscript.
Author details
1Unit of Biostatistics, Regina Elena National Cancer Institute, Rome 00144,
Italy. 2Division of Medical Oncology B, Regina Elena National Cancer Institute,
Rome 00144, Italy. 3Medical Oncology Unit, Department of Experimental and
Clinical Sciences, University “G. d’Annunzio”, Chieti 66013, Italy. 4Department
of Oncology, “S.S. Trinita`” Hospital, Sora (FR) 00039, Italy. 5Department of
Oncology, “S.S. Annunziata” Hospital, Chieti 66013, Italy.
Received: 3 September 2013 Accepted: 7 November 2013
Published: 11 November 2013
References
1. De Angelis R, Tavilla A, Verdecchia A, Scoppa S, Hachey M, Feuer EJ,
Mariotto AB: Breast cancer survivors in the United States: geographic
variability and time trends, 2005–2015. Cancer 2009, 115(9):1954–1966.
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin
2013, 63(1):11–30.
3. Piscitelli P, Barba M, Crespi M, Di Maio M, Santoriello A, D’Aiuto M, Fucito A,
Losco A, Pentimalli F, Maranta P, et al: The burden of breast cancer in
Italy: mastectomies and quadrantectomies performed between 2001
and 2008 based on nationwide hospital discharge records. J Exp Clin
Cancer Res 2012, 31:96–104.
4. Vrdoljak E, Wojtukiewicz MZ, Pienkowski T, Bodoky G, Berzinec P, Finek J,
Todorovic V, Borojevic N, Croitoru A: Cancer epidemiology in Central,
South and Eastern European countries. Croat Med J 2011, 52(4):478–487.
5. Australian Institute of Health and Welfare: Cancer in Australia: Actual
incidence data from 1991 to 2009 and mortality data from 1991 to 2010
with projections to 2012. Asia Pac J Clin Oncol 2013, 9(3):199–213.6. van Hezewijk M, Hille ET, Scholten AN, Marijnen CA, Stiggelbout AM, van de
Velde CJ: Professionals’ opinion on follow-up in breast cancer patients;
perceived purpose and influence of patients’ risk factors. Eur J Surg Oncol
2011, 37(3):217–224.
7. Arnstein NB, Harbert JC, Byrne PJ: Efficacy of bone and liver scanning in
breast cancer patients treated with adjuvant chemotherapy. Cancer 1984,
54(10):2243–2247.
8. Evans DM, Wright DJ: The role of bone and liver scans in surveying
patients with breast cancer for metastatic disease. Am Surg 1987,
53(10):603–605.
9. Feig SA: Imaging techniques and guidelines for evaluation and follow-up
of breast cancer patients. Crit Rev Diagn Imaging 1987, 27(1):1–16.
10. Kunkler IH, Merrick MV, Rodger A: Bone scintigraphy in breast cancer:
a nine-year follow-up. Clin Radiol 1985, 36(3):279–282.
11. The GIVIO Investigators: Impact of follow-up testing on survival and
health-related quality of life in breast cancer patients. A multicenter
randomized controlled trial. JAMA 1994, 271(20):1587–1592.
12. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V:
Intensive diagnostic follow-up after treatment of primary breast cancer.
A randomized trial. National Research Council Project on Breast Cancer
follow-up. JAMA 1994, 271(20):1593–1597.
13. Rojas MP, Telaro E, Russo A, Fossati R, Confalonieri C, Liberati A: Follow-up
strategies for women treated for early breast cancer. Cochrane Database
Syst Rev 2000, 4, CD001768.
14. Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, Palli D, del Roselli
TM, Liberati A: Follow-up strategies for women treated for early breast
cancer. Cochrane Database Syst Rev 2005, 1, CD001768.
15. Grunfeld E, Fitzpatrick R, Mant D, Yudkin P, Adewuyi-Dalton R, Stewart J, Cole
D, Vessey M: Comparison of breast cancer patient satisfaction with follow-
up in primary care versus specialist care: results from a randomized
controlled trial. Br J Gen Pract 1999, 49(446):705–710.
16. Grunfeld E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart J, Fitzpatrick
R, Vessey M: Routine follow up of breast cancer in primary care: randomised
trial. BMJ 1996, 313(7058):665–669.
17. Gulliford T, Opomu M, Wilson E, Hanham I, Epstein R: Popularity of less
frequent follow up for breast cancer in randomised study: initial findings
from the hotline study. BMJ 1997, 314(7075):174–177.
18. Palli D, Russo A, Saieva C, Ciatto S, Rosselli Del Turco M, Distante V, Pacini P:
Intensive vs clinical follow-up after treatment of primary breast cancer:
10-year update of a randomized trial. National Research Council Project
on Breast Cancer Follow-up. JAMA 1999, 281(17):1586.
19. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F,
Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolf AC, Somerfield MR,
Davidson NE, American Society of Clinical Oncology: Breast cancer follow-
up and management after primary treatment: American Society of
Clinical Oncology clinical practice guideline update. J Clin Oncol 2013,
31(7):961–965.
20. Grunfeld E, Dhesy-Thind S, Levine M: Clinical practice guidelines for the
care and treatment of breast cancer: follow-up after treatment for breast
cancer (summary of the 2005 update). CMAJ 2005, 172(10):1319–1320.
21. Montgomery DA, Krupa K, Cooke TG: Follow-up in breast cancer: does
routine clinical examination improve outcome? A systematic review of
the literature. Br J Cancer 2007, 97(12):1632–1641.
22. de Bock GH, Bonnema J, van der Hage J, Kievit J, van de Velde CJ:
Effectiveness of routine visits and routine tests in detecting isolated
locoregional recurrences after treatment for early-stage invasive breast
cancer: a meta-analysis and systematic review. J Clin Oncol 2004,
22(19):4010–4018.
23. Collins RF, Bekker HL, Dodwell DJ: Follow-up care of patients treated for
breast cancer: a structured review. Cancer Treat Rev 2004, 30(19):19–35.
24. Molino A: What is the best follow-up methodology in early breast
cancer? Breast 2008, 17(1):1–2.
25. Leoni M, Sadacharan R, Louis D, Falcini F, Rabinowitz C, Cisbani L, De Palma
R, Yuen E, Grilli R: Variation among local health units in follow-up care of
breast cancer patients in Emilia-Romagna, Italy. Tumori 2013, 99(1):30–34.
26. Grandjean I, Kwast AB, de Vries H, Klaase J, Schoevers WJ, Siesling S:
Evaluation of the adherence to follow-up care guidelines for women
with breast cancer. Eur J Oncol Nurs 2012, 16(3):281–285.
27. Margenthaler JA, Allam E, Chen L, Virgo KS, Kulkarni UM, Patel AP, Johnson FE:
Surveillance of patients with breast cancer after curative-intent primary
treatment: current practice patterns. J Oncol Pract 2012, 8(2):79–83.
Sperduti et al. Journal of Experimental & Clinical Cancer Research 2013, 32:89 Page 8 of 12
http://www.jeccr.com/content/32/1/8928. Grunfeld E, Hodgson DC, Del Giudice ME, Moineddin R: Population-based
longitudinal study of follow-up care for breast cancer survivors. J Oncol
Pract 2010, 6(4):174–181.
29. Zhou WB, Zhang PL, Liu XA, Yang T, He W: Innegligible musculoskeletal
disorders caused by zoledronic acid in adjuvant breast cancertreatment:
a meta-analysis. J Exp Clin Cancer Res 2011, 30(1):72–78.
30. Sagawa Y Jr, Armand S, Lubbeke A, Hoffmeyer P, Fritschy D, Suva D, Turcot
K: Associations between gait and clinical parameters in patients with
severe knee osteoarthritis: A multiple correspondence analysis.
Clin Biomech (Bristol, Avon) 2013, 28(3):299–305.
31. Aihara T, Takatsuka Y, Ohsumi S, Aogi K, Hozumi Y, Imoto S, Mukai H, Iwata
H, Watanabe T, Shimizu C, Nakagami K, Tamura M, Ito T, Masuda N, Ogino
N, Hisamatsu K, Mitsuyama S, Abe H, Tanaka S, Yamaguchi T, Ohashi Y:
Phase III randomized adjuvant study of tamoxifen alone versus
sequential tamoxifen and anastrozole in Japanese postmenopausal
women with hormone-responsive breast cancer: N-SAS BC03 study.
Breast Cancer Res Treat 2010, 121(2):379–387.
32. Amadori D, Silvestrini R, Lena M, Boccardo F, Rocca A, Scarpi E, Schittulli F,
Brandi M, Maltoni R, Serra P, Ponzone R, Biglia N, Gianni L, Tienghi A, Valerio
MR, Bonginelli P, Amaducci L, Faedi M, Baldini E, Paradiso A: Randomized
phase III trial of adjuvant epirubicin followed by cyclophosphamide,
methotrexate, and 5-fluorouracil (CMF) versus CMF followed by
epirubicin in patients with node-negative or 1–3 node-positive rapidly
proliferating breast cancer. Breast Cancer Res Treat 2011, 125(3):775–784.
33. Arriagada R, Spielmann M, Koscielny S, Le Chevalier T, Delozier T, Rémé-
Saumon M, Ducourtieux M, Tursz T, Hill C: Results of two randomized trials
evaluating adjuvant anthracycline-based chemotherapy in 1 146 patients
with early breast cancer. Acta Oncol 2005, 44(5):458–466.
34. Arriagada RLM, Spielmann M, Mauriac L, Bonneterre J, Namer M, Delozier T,
Hill C, Tursz T: Randomized trial of adjuvant ovarian suppression in 926
premenopausal patients with early breast cancer treated with adjuvant
chemotherapy. Ann Oncol 2005, 16(3):389–396.
35. Bedognetti D, Sertoli MR, Pronzato P, Del Mastro L, Venturini M, Taveggia P,
Zanardi E, Siffredi G, Pastorino S, Queirolo P, Gardin G, Wang E, Monzeglio
C, Boccardo F, Bruzzi P: Concurrent vs Sequential Adjuvant Chemotherapy
and Hormone Therapy in Breast Cancer: A Multicenter Randomized
Phase III Trial. J Natl Cancer Inst 2011, 103(20):1529–1539.
36. Boccardo FRA, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G,
Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia
N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P:
Switching to Anastrozole Versus Continued Tamoxifen Treatment of
Early Breast Cancer: Preliminary Results of the Italian Tamoxifen
Anastrozole Trial. J Clin Oncol 2005, 23(22):5138–5147.
37. Burnell M, Levine MN, Chapman JAW, Bramwell V, Gelmon K, Walley B,
Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O’Brien
P, Shepherd LE: Cyclophosphamide, Epirubicin, and Fluorouracil Versus
Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel
Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in
Node-Positive or High-Risk Node-Negative Breast Cancer. J Clin Oncol
2009, 28(1):77–82.
38. Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M,
Coleman RE, Tubiana-Mathieu N, den Boer MO, Wardley A, Kilburn LS,
Cooper D, Thomas MW, Reise JA, Wilkinson K, Hupperets P: Randomized,
Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin
Alone in Postmenopausal Patients With Node-Positive Breast Cancer.
J Clin Oncol 2011, 29(24):3247–3254.
39. Coombes RC HE, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE,
Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman
RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart
A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, Van De Velde
C, Intergroup Exemestane Study: A randomized trial of exemestane after
two to three years of tamoxifen therapy in postmenopausal women
with primary breast cancer. N Engl J Med 2004, 350(11):1081–1092.
40. Davidson NEONA, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD:
Chemoendocrine Therapy for Premenopausal Women With Axillary
Lymph Node-Positive, Steroid Hormone Receptor-Positive Breast Cancer:
Results From INT 0101 (E5188). J Clin Oncol 2005, 23(25):5973–5982.
41. De Placido S, De Laurentiis M, De Lena M, Lorusso V, Paradiso A, D’Aprile M,
Pistillucci G, Farris A, Sarobba MG, Palazzo S, Manzione L, Adamo V, Palmeri
S, Ferraù F, Lauria R, Pagliarulo C, Petrella G, Limite G, Costanzo R, Bianco
AR, GOCSI Cooperative Group: A randomised factorial trial of sequentialdoxorubicin and CMF vs CMF and chemotherapy alone vs
chemotherapy followed by goserelin plus tamoxifen as adjuvant
treatment of node-positive breast cancer. Br J Cancer 2005,
14(3):467–474.
42. Eiermann W, Graf E, Ataseven B, Conrad B, Hilfrich J, Massinger-Biebl H,
Vescia S, Loibl S, von Minckwitz G, Schumacher M, Kaufmann M: Dose-in-
tensified epirubicin versus standard-dose epirubicin/cyclophosphamide
followed by CMF in breast cancer patients with 10 or more positive
lymph nodes: Results of a randomised trial (GABG-IV E-93) – The German
Adjuvant Breast Cancer Group. Eur J Cancer 2010, 46(1):84–94.
43. Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M,
Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva
A, Buyse M, Drevot P, Taupin H, Mackey JR: Phase III Study of Doxorubicin/
Cyclophosphamide With Concomitant Versus Sequential Docetaxel As
Adjuvant Treatment in Patients With Human Epidermal Growth Factor
Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial. J Clin
Oncol 2011, 29(29):3877–3884.
44. Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S,
Edlund P, Ewertz M, de Graaf PW, Kamby C, Nielsen DL: Similar Efficacy for
Ovarian Ablation Compared With Cyclophosphamide, Methotrexate, and
Fluorouracil: From a Randomized Comparison of Premenopausal
Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer.
J Clin Oncol 2006, 24(31):4956–4962.
45. Focan C, Beauduin M, Majois F, Canon JL, Cusumano G, Focan-Henrard D,
Lobelle JP: High-dose oral medroxyprogesterone acetate or tamoxifen as
adjuvant hormone therapy for node-negative early-stage breast cancer:
randomized trial with 7-year update. Clin Breast Cancer 2004, 5(2):136–141.
46. Fountzilas GSG, Kouvatseas G, Polychronis A, Klouvas G, Samantas E,
Zamboglou N, Kyriakou K, Adamou A, Pectasidis D, Ekonomopoulos T,
Kalofonos HP, Bafaloukos D, Georgoulias V, Razis E, Koukouras D, Zombolas
V, Kosmidis P, Skarlos D, Pavlidis N, Hellenic Cooperative Oncology Group:
Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal
patients with breast cancer and one to nine infiltrated nodes: five-year
results of the Hellenic Cooperative Oncology Group randomized HE 10/
92 study. Am J Clin Oncol 2004, 27(1):57–67.
47. Fumoleau P, Kerbrat P, Romestaing P, Fargeot P, Brémond A, Namer M,
Schraub S, Goudier MJ, Mihura J, Monnier A, Clavère P, Serin D, Seffert P,
Pourny C, Facchini T, Jacquin JP, Sztermer JF, Datchary J, Ramos R, Luporsi
E: Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-
Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast
Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study
Group 01 Trial. J Clin Oncol 2003, 21(2):298–305.
48. Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M,
Kalofonos HP, Eleftheraki AG, Timotheadou E, Bafaloukos D, Christodoulou
C, Markopoulos C, Briasoulis E, Papakostas P, Samantas E, Kosmidis P,
Stathopoulos GP, Karanikiotis C, Pectasides D, Dimopoulos MA, Fountzilas G:
Postoperative dose-dense sequential versus concomitant administration
of epirubicin and paclitaxel in patients with node-positive breast cancer:
5-year results of the Hellenic Cooperative Oncology Group HE 10/00
phase III Trial. Breast Cancer Res Treat 2012, 132(2):609–619.
49. Goldstein LJ, O’Neill A, Sparano JA, Perez EA, Shulman LN, Martino S,
Davidson NE: Concurrent Doxorubicin Plus Docetaxel Is Not More
Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in
Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North
American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008,
26(25):4092–4099.
50. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S,
Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan
DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L:
Improved outcomes from adding sequential Paclitaxel but not from
escalating Doxorubicin dose in an adjuvant chemotherapy regimen for
patients with node-positive primary breast cancer. J Clin Oncol 2003,
21(6):976–983.
51. Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky
TM, Wold LE, Donohue JH, Goetz MP, Perez EA: Randomized trial of
tamoxifen alone or combined with fluoxymesterone as adjuvant therapy
in postmenopausal women with resected estrogen receptor positive
breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
Breast Cancer Res Treat 2006, 98(2):217–222.
52. International Breast Cancer Study Group (IBCSG): Endocrine responsiveness
and tailoring adjuvant therapy for postmenopausal lymph node-
Sperduti et al. Journal of Experimental & Clinical Cancer Research 2013, 32:89 Page 9 of 12
http://www.jeccr.com/content/32/1/89negative breast cancer: a randomized trial. J Natl Cancer Inst 2002,
94(14):1054–1065.
53. International Breast Cancer Study Group (IBCSG), Castiglione Gertsch M,
O’Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M,
Gelber RD: Adjuvant Chemotherapy Followed by Goserelin Versus Either
Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer:
A Randomized Trial. J Natl Cancer Inst 2003, 95(24):1833–1846.
54. International Breast Cancer Study Group PO: Toremifene and tamoxifen
are equally effective for early-stage breast cancer: first results of
International Breast Cancer Study Group Trials 12–93 and 14–93.
Ann Oncol 2004, 15(12):1749–1759.
55. International Breast Cancer Study Group CM, Gelber S, Goldhirsch A, Aebi S,
Castiglione Gertsch M, Price KN, Coates AS, Gelber RD: Tamoxifen After
Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-
Positive Breast Cancer: International Breast Cancer Study Group Trial
13–93. J Clin Oncol 2006, 24(9):1332–1341.
56. Basser RL, O’Neill A, Martinelli G, Green MD, Peccatori F, Cinieri S, Coates AS,
Gelber RD, Aebi S, Castiglione-Gertsch M, Viale G, Price KN, Goldhirsch A:
Multicycle dose-intensive chemotherapy for women with high-risk
primary breast cancer: results of International Breast Cancer Study Group
Trial 15–95. J Clin Oncol 2006, 24(3):370–378.
57. Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert
M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette
V, Samonigg H, Austrian Breast and Colorectal Cancer Study Group Trial 5:
Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus
Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the
Superiority of Treatment With Endocrine Blockade in Premenopausal
Patients With Hormone-Responsive Breast Cancer–Austrian Breast and
Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002, 20(24):4621–4627.
58. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J,
Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M,
Wolfgang J, ABCSG and the GABG: Switching of postmenopausal women
with endocrine-responsive early breast cancer to anastrozole after 2
years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO
95 trial. Lancet 2005, 366(9484):455–462.
59. Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S,
McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ,
Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA,
Meyer WG, Asmar L: Phase III Trial Comparing Doxorubicin Plus
Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant
Therapy for Operable Breast Cancer. J Clin Oncol 2006, 24(34):5381–5387.
60. Kaufmann M, Graf E, Jonat W, Eiermann W, Vescia S, Geberth M, Conrad B,
Gademann G, Albert U-S, Loibl S, von Minckwitz G, Schumacher M, German
Adjuvant Breast Cancer Study Group (GABG): A randomised trial of
goserelin versus control after adjuvant, risk-adapted chemotherapy in
premenopausal patients with primary breast cancer – GABG-IV B-93.
Eur J Cancer 2007, 43(16):2351–2358.
61. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von
Minckwitz G: Improved Overall Survival in Postmenopausal Women With
Early Breast Cancer After Anastrozole Initiated After Treatment With
Tamoxifen Compared With Continued Tamoxifen: The ARNO 95 Study.
J Clin Oncol 2007, 25(19):2664–2670.
62. Kaufmann MGE, Jonat W, Eiermann W, Geberth M, Albert US, Gademann G,
Conrad B, Stahl K, von Minckwitz G, Schumacher M, German Adjuvant
Breast Cancer Group: Tamoxifen Versus Control After Adjuvant, Risk-
Adapted Chemotherapy in Postmenopausal, Receptor-Negative Patients
With Breast Cancer: A Randomized Trial (GABG-IV D-93)–The German
Adjuvant Breast Cancer Grou. J Clin Oncol 2005, 23(31):7842–7848.
63. Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S,
Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y, Adjuvant CEF Research
Group for Breast Cancer: Randomized trial of cyclophosphamide,
epirubicin, and fluorouracil chemotherapy compared with
cyclophosphamide, methotrexate, and fluorouracil with node-positive
breast cancer in Japan. Breast Cancer 2010, 17(3):190–198.
64. Lewis JD, Chagpar AB, Shaughnessy EA, Nurko J, McMasters K, Edwards MJ:
Excellent outcomes with adjuvant toremifene or tamoxifen in early
stage breast cancer. Cancer 2010, 116(10):2307–2315.
65. Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, Vukelja
SJ, Sandbach J, Holmes F, Sedlacek S, Pippen J, Lindquist D, McIntyre K,
Blum JL, Modiano MR, Boehm KA, Zhan F, Asmar L, Robert N: Phase III
Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed byPaclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by
Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast
Cancer. J Clin Oncol 2010, 28(18):2958–2965.
66. Love RR, Duc NB, Allred DC, Binh NC, Dinh NV, Kha NN, Thuan TV, Mohsin
SK, le Roanh D, Khang HX, Tran TL, Quy TT, Thuy NV, Thé PN, Cau TT, Tung
ND, Huong DT, le Quang M, Hien NN, Thuong L, Shen TZ, Xin Y, Zhang Q,
Havighurst TC, Yang YF, Hillner BE, DeMets DL: Oophorectomy and
Tamoxifen Adjuvant Therapy in Premenopausal Vietnamese and Chinese
Women With Operable Breast Cancer. J Clin Oncol 2002, 20(10):2559–2566.
67. Mamounas EPBJ, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B,
Wickerham DL, Yothers G, Soran A, Wolmark N: Paclitaxel After
Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for
Node-Positive Breast Cancer: Results From NSABP B-28. J Clin Oncol 2005,
23(16):3686–3696.
68. Martin M, Segui MA, Anton A, Ruiz A, Ramos M, Adrover E, Aranda I,
Rodriguez Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez Del
Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Muñoz M, Lopez Vega JM, Mel
JR, Munarriz B, Llorca C, Jara C, Alba E, Florian J, Li J, Lopez Garcia Asenjo JA,
Saez A, Rios MJ, Almenar S, Peiro G, Lluch A, GEICAM 9805 Investigators:
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. N Engl J
Med 2010, 363(23):2200–2210.
69. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M,
Munarriz B, Rodriguez CA, Crespo C, de Alava E, López García-Asenjo JA,
Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M,
Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A,
Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E,
Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM,
GEICAM 9906 Study Investigators: Randomized Phase 3 Trial of Fluorouracil,
Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early
Breast Cancer. J Natl Cancer Inst 2008, 100(11):805–814.
70. Martin MPT, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E,
Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth
J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C,
Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz
S, Jacobs P, Murawsky M, Riva A, Vogel C, Breast Cancer International
Research Group 001 Investigators: Adjuvant Docetaxel for Node-Positive
Breast Cancer. N Engl J Med 2005, 352(22):2302–2313.
71. Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C,
Werner C, Ziske C, Kirchner H, Metzner B: Comparison of rapidly cycled
tandem high-dose chemotherapy plus peripheral-blood stem-cell
support versus dose-dense conventional chemotherapy for adjuvant
treatment of high-risk breast cancer: results of a multicentre phase III
trial. Lancet 2005, 366(9501):1935–1944.
72. Park Y, Okamura K, Mitsuyama S, Saito T, Koh J, Kyono S, Higaki K, Ogita M,
Asaga T, Inaji H, Komichi H, Kohno N, Yamazaki K, Tanaka F, Ito T, Nishikawa
H, Osaki A, Koyama H, Suzuki T: Uracil-tegafur and tamoxifen vs
cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-
operative adjuvant therapy for stage I, II, or IIIA lymph node-positive
breast cancer: a comparative study. Br J Cancer 2009, 101(4):598–604.
73. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King
KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux
A, Perez EA, Zheng P, Geyer CE Jr, Swain SM, Costantino JP, Mamounas EP,
Wolmark N: Oral clodronate for adjuvant treatment of operable breast
cancer (National Surgical Adjuvant Breast and Bowel Project protocol
B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol
2012, 13(7):734–742.
74. Piccart-Gebhart MJPM, Leyland-Jones B, Goldhirsch A, Untch M, Smith I,
Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH,
Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U,
Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V,
Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant
(HERA) Trial Study Team: Trastuzumab after Adjuvant Chemotherapy in
HER2-Positive Breast Cancer. N Engl J Med 2005, 335(16):1659–1672.
75. Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P,
Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M,
Kubista E, Samonigg H, Austrian Breast And Colorectal Cancer Study Group:
Randomised trial: One cycle of anthracycline-containing adjuvant chemother-
apy compared with six cycles of CMF treatment in node-positive, hormone
receptor-negative breast cancer patients. Onkologie 2003, 26(2):115–119.
76. Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris
S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L,
Sperduti et al. Journal of Experimental & Clinical Cancer Research 2013, 32:89 Page 10 of 12
http://www.jeccr.com/content/32/1/89Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D:
FEC versus sequential docetaxel followed by epirubicin/
cyclophosphamide as adjuvant chemotherapy in women with axillary
node-positive early breast cancer: a randomized study of the Hellenic
Oncology Research Group (HORG). Breast Cancer Res Treat 2010,
119(1):95–104.
77. Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent
SF, Walde D, Vandenberg TA, Findlay B, O’Reilly SE, Wilson CF, Han L, Piura
E, Whelan TJ, Pollak MN: Randomized trial of tamoxifen versus combined
tamoxifen and octreotide LAR Therapy in the adjuvant treatment of
early-stage breast cancer in postmenopausal women: NCIC CTG MA.
14. J Clin Oncol 2011, 29(29):3869–3876.
78. Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann
M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A,
Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J,
Asselain B: Sequential Adjuvant Epirubicin-Based and Docetaxel
Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC
PACS 01 Trial. J Clin Oncol 2006, 24(36):5664–5671.
79. Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest
EE, Hupperets P, Van Tinteren H, Peterse HL, TenVergert EM, De Vries EG:
Netherlands Working Party on Autologous Transplantation in Solid
Tumors: High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue
for High-Risk Breast Cancer. N Engl J Med 2003, 349(1):7–16.
80. Rydén L, Jönsson P-E, Chebil G, Dufmats M, Fernö M, Jirström K, Källström
A-C, Landberg G, Stål O, Thorstenson S, Nordenskjöld B: Two years of
adjuvant tamoxifen in premenopausal patients with breast cancer: a
randomised, controlled trial with long-term follow-up. Eur J Cancer 2005,
41(2):256–264.
81. Sacco MVM, Belfiglio M, Pellegrini F, De Berardis G, Franciosi M, Nicolucci A,
Italian Interdisciplinary Group for Cancer Care Evaluation: Randomized Trial
of 2 Versus 5 Years of Adjuvant Tamoxifen for Women Aged 50 Years or
Older With Early Breast Cancer: Italian Interdisciplinary Group for Cancer
Evaluation Study of Adjuvant Treatment in Breast Cancer 01. J Clin Oncol
2003, 21(12):2276–2281.
82. Schmid MJR, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K,
Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C,
Fridrik M, Wette V, Steger G, Hausmaninger H: Randomized Trial of
Tamoxifen Versus Tamoxifen Plus Aminoglutethimide as Adjuvant
Treatment in Postmenopausal Breast Cancer Patients With Hormone
Receptor-Positive Disease: Austrian Breast and Colorectal Cancer Study
Group Trial 6. J Clin Oncol 2003, 21(6):984–990.
83. Schmid P, Untch M, Kosse V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U,
Maubach L, Meurer J, Wallwiener D, Possinger K: Leuprorelin Acetate
Every-3-Months Depot Versus Cyclophosphamide, Methotrexate, and
Fluorouracil As Adjuvant Treatment in Premenopausal Patients With
Node-Positive Breast Cancer: The TABLE Study. J Clin Oncol 2007,
25(18):2509–2515.
84. Schmid P, Untch M, Wallwiener D, Kosse V, Bondar G, Vassiljev L, Tarutinov
V, Kienle E, Luftner D, Possinger K, TABLE-study (Takeda Adjuvant Breast can-
cer study with Leuprorelin Acetate): Cyclophosphamide, methotrexate and
fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as
adjuvant treatment of node-positive, premenopausal breast cancer
patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast
cancer study with Leuprorelin Acetate). Anticancer Res 2002,
22(4):2325–2332.
85. Spielmann M, Roche H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra
JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M,
Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL,
Penault-Llorca F: Trastuzumab for Patients With Axillary-Node-Positive
Breast Cancer: Results of the FNCLCC-PACS 04 Trial. J Clin Oncol 2009,
27(36):6129–6134.
86. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T,
ATAC Trialists’ Group: Anastrozole alone or in combination with
tamoxifen versus tamoxifen alone for adjuvant treatment of
postmenopausal women with early breast cancer: first results of the
ATAC randomised trial. Lancet 2002, 359(9324):2131–2139.
87. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF,
Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley
A, Price KN, Goldhirsch A: A comparison of letrozole and tamoxifen in
postmenopausal women with early breast cancer. N Engl J Med 2005,
353(26):2747–2757.88. Tokuda Y, Tajima T, Narabayashi M, Takeyama K, Watanabe T, Fukutomi T,
Chou T, Sano M, Igarashi T, Sasaki Y, Ogura M, Miura S, Okamoto S, Ogita M,
Kasai M, Kobayashi T, Fukuda H, Takashima S, Tobinai K, Autologous Bone
Marrow Transplantation Study Group;Breast Cancer Study Group of the
Japan Clinical Oncology Group (JCOG): Phase III study to evaluate the use
of high-dose chemotherapy as consolidation of treatment for high-risk
postoperative breast cancer: Japan Clinical Oncology Group study, JCOG
9208. Cancer Sci 2008, 99(1):145–51.
89. Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, Testore F,
Brema F, Pronzato P, Cavazzini G, Sertoli MR, Canavese G, Rosso R, Bruzzi P:
Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients:
Results From a Randomized Trial. J Natl Cancer Inst 2005,
97(23):1724–1733.
90. Vici P, Brandi M, Giotta F, Foggi P, Schittulli F, Di Lauro L, Gebbia N,
Massidda B, Filippelli G, Giannarelli D, Di Benedetto A, Mottolese M, Colucci
G, Lopez M: A multicenter phase III prospective randomized trial of
high-dose epirubicin in combination with cyclophosphamide (EC) versus
docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo
Oncologico Italia Meridionale) 9902 study. Ann Oncol 2012,
23(5):1121–1129.
91. von Minckwitz G, Graf E, Geberth M, Eiermann W, Jonat W, Conrad B,
Brunnert K, Gerber B, Vescia S, Wollert J, Kaufmann M: CMF versus
goserelin as adjuvant therapy for node-negative, hormone-receptor-
positive breast cancer in premenopausal patients: A randomised trial
(GABG trial IV-A-93). Eur J Cancer 2006, 42(12):1780–1788.
92. Winzer KJ, Sauer R, Sauerbrei W, Schneller E, Jaeger W, Braun M, Dunst J,
Liersch T, Zedelius M, Brunnert K, Guski H, Schmoor C, Schumacher M,
German Breast Cancer Study Group: Radiation therapy after breast-
conserving surgery. Eur J Cancer 2004, 40(7):998–1005.
93. Zander ARKN, Schmoor C, Krüger W, Möbus V, Frickhofen N, Metzner B,
Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K,
Trümper L, Kreienberg R, Carstensen M, Schmidt EH, Jänicke F, Schumacher
M, Jonat W: High-Dose Chemotherapy With Autologous Hematopoietic
Stem-Cell Support Compared With Standard-Dose Chemotherapy in
Breast Cancer Patients With 10 or More Positive Lymph Nodes: First
Results of a Randomized Trial. J Clin Oncol 2004, 22(12):2273–2283.
94. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM,
Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L,
Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE: Adjuvant tamoxifen
and exemestane in early breast cancer (TEAM): a randomised phase
3 trial. Lancet 2011, 377(9762):321–331.
95. Kerbrat P, Roché H, Bonneterre J, Veyret C, Lortholary A, Monnier A,
Fumoleau P, Fargeot P, Namer M, Chollet P, Goudier MJ, Audhuy B, Simon
H, Montcuquet P, Eymard JC, Walter S, Clavère P, Guastalla JP, French
adjuvant Study Group: Epirubicin–vinorelbine vs FEC100 for node-
positive, early breast cancer: French Adjuvant Study Group 09 trial.
Br J Cancer 2007, 96(11):1633–1638.
96. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau
CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD,
Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne
CK, Breast Cancer Intergroup of North America: Adjuvant chemotherapy
and timing of tamoxifen in postmenopausal patients with endocrine-
responsive, node-positive breast cancer: a phase 3, open-label,
randomised controlled trial. Lancet 2009, 374(9707):2055–2063.
97. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ,
Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd
D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB,
Norton L: Randomized trial of dose-dense versus conventionally
scheduled and sequential versus concurrent combination chemotherapy
as postoperative adjuvant treatment of node-positive primary breast
cancer: first report of Intergroup Trial C9741/Cancer and Leukemia
Group B Trial 9741. J Clin Oncol 2003, 21(8):1431–1439.
98. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil
M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U,
Peterson J, Davies C, Hiley V, Gregory W, Bell R, AZURE Investigators:
Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011,
365(15):1396–1405.
99. Dubsky PC, Jakesz R, Mlineritsch B, Postlberger S, Samonigg H, Kwasny W,
Tausch C, Stoger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P,
Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R,
Filipcic L, Gnant M: Tamoxifen and Anastrozole As a Sequencing Strategy:
Sperduti et al. Journal of Experimental & Clinical Cancer Research 2013, 32:89 Page 11 of 12
http://www.jeccr.com/content/32/1/89A Randomized Controlled Trial in Postmenopausal Patients With
Endocrine-Responsive Early Breast Cancer From the Austrian Breast and
Colorectal Cancer Study Group. J Clin Oncol 2012, 30(7):722–728.
100. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O’Reilly S, Verrill M,
Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C,
Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt
C, Hall E, Bliss JM, TACT Trial Management Group: TACT Trialists: Sequential
docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an
open-label, phase III, randomised controlled trial. Lancet Oncol 2009,
373(9676):1681–1692.
101. Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjold B,
Lang I, Jakesz R, Vorobiof D, Gutiérrez J, van Hazel G, Dolci S, Jamin S,
Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-
Gebhart M, BIG 02–98 Collaborative Group: Adjuvant Chemotherapy With
Sequential or Concurrent Anthracycline and Docetaxel: Breast International
Group 02 98 Randomized Trial. J Natl Cancer Inst 2008, 100(2):121–133.
102. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger
S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H,
Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F,
Stierer M, Rücklinger E, Greil R, ABCSG-12 Trial Investigators, Marth C:
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
N Engl J Med 2009, 360(7):679–691.
103. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M,
Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L,
Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL: A Randomized Trial
of Letrozole in Postmenopausal Women after Five Years of Tamoxifen
Therapy for Early-Stage Breast Cancer. N Engl J Med 2003,
349(19):1793–1802.
104. Hughes KSSL, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J,
Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C,
Wood W, Sugarbaker D, Henderson IC, Norton L, Cancer and Leukemia
Group B; Radiation Therapy Oncology Group; Eastern Cooperative Oncology
Group: Lumpectomy plus tamoxifen with or without irradiation in
women 70 years of age or older with early breast cancer. N Engl J Med
2004, 351(10):971–977.
105. Hutchins LFGS, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C,
Rivkin SE, Osborne CK: Randomized, Controlled Trial of
Cyclophosphamide, Methotrexate, and Fluorouracil Versus
Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without
Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment
Results of Intergroup Protocol INT-0102. J Clin Oncol 2005, 23:8313–8321.
106. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A,
Tanner M, Asola R, Kokko R, Ahlgren J, Auvinen P, Hemminki A, Paija O, Helle
L, Nuortio L, Villman K, Nilsson G, Lahtela SL, Lehtiö K, Pajunen M, Poikonen
P, Nyandoto P, Kataja V, Bono P, Leinonen M, Lindman H, FinXX Study
Investigators: Adjuvant capecitabine in combination with docetaxel and
cyclophosphamide plus epirubicin for breast cancer: an open-label,
randomised controlled trial. Lancet Oncol 2009, 10(12):1145–1151.
107. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R,
Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T,
Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS,
Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I,
Isola J, FinHer Study Investigators: Adjuvant docetaxel or vinorelbine
with or without trastuzumab for breast cancer. N Engl J Med 2006,
354(8):809–820.
108. Leonard RCF, Lind M, Twelves C, Coleman R, van Belle S, Wilson C,
Ledermann J, Kennedy I, Barrett-Lee P, Perren T, Verrill M, Cameron D, Foster
E, Yellowlees A, Crown J, Anglo-Celtic Cooperative Oncology Group:
Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-
Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk
Breast Cancer Patients: A Randomized Trial. J Natl Cancer Inst 2004,
96(14):1076–1083.
109. Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn
W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G,
Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M: Intense
Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and
Cyclophosphamide Compared With Conventionally Scheduled
Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of
an AGO Phase III Study. J Clin Oncol 2010, 28(17):2874–2880.
110. Moore HCF, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE, Hudis C,
Wolff AC, Ingle JN, Chew HK, Elias AD, Livingston RB, Martino S, SouthwestOncology Group/Intergroup Study 9623: Intensive Dose-Dense Compared
With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast
Cancer: Southwest Oncology Group/Intergroup Study 9623. J Clin Oncol
2007, 25(13):1677–1682.
111. Petit T, Borel C, Theobald S, Serin D, Rodier JF, Prevot G, Brettes JP, Klein T:
Randomized multicentric study of perioperative chemotherapy with
mitoxantrone in early breast cancer. Ann Surg Oncol 2003, 10(4):369–375.
112. Pico CMM, Jara C, Barnadas A, Pelegri A, Balil A, Camps C, Frau A,
Rodriguez-Lescure A, Lopez-Vega JM, De La Haba J, Tres A, Alvarez I, Alba E,
Arcusa A, Oltra A, Batista N, Checa T, Perez-Carrion R, Curto J, GEICAM
Group: Epirubicin-cyclophosphamide adjuvant chemotherapy plus
tamoxifen administered concurrently versus sequentially: randomized
phase III trial in postmenopausal node-positive breast cancer patients.
A GEICAM 9401 study. Ann Oncol 2004, 15(1):79–87.
113. Poole CJEH, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK,
Fernando IN, Brunt AM, O’Reilly SM, Crawford SM, Rea DW, Simmonds P,
Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RC, Twelves CJ,
NEAT Investigators and the SCTBG: Epirubicin and cyclophosphamide,
methotrexate, and fluorouracil as adjuvant therapy for early breast
cancer. N Engl J Med 2006, 355(18):1851–1862.
114. Rao RD, Cobleigh MA, Gray R, Graham ML 2nd, Norton L, Martino S, Budd
GT, Ingle JN, Wood WC: Phase III double-blind, placebo-controlled,
prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and
fenretinide in postmenopausal women with positive receptors (EB193):
an intergroup trial coordinated by the Eastern Cooperative Oncology
Group. Med Oncol 2011, 1(28):S39–47.
115. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE,
Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM,
Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB,
Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark
N: Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive
Breast Cancer. N Engl J Med 2005, 353(16):1673–1684.
116. Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, Murakami
S, Yamamoto Y, Kashiwaba M, Iwata H, Uemura Y, Ohashi Y: Evaluation of
trastuzumab without chemotherapy as a post-operative adjuvant
therapy in HER2-positive elderly breast cancer patients: randomized
controlled trial [RESPECT (N-SAS BC07)]. Jpn J Clin Oncol 2011, 41(5):709–712.
117. Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O’Regan R,
Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H,
Winer EP, Hudis C: Six cycles of doxorubicin and cyclophosphamide or
Paclitaxel are not superior to four cycles as adjuvant chemotherapy for
breast cancer in women with zero to three positive axillary nodes:
Cancer and Leukemia Group B 40101. J Clin Oncol 2012, 30(33):4071–4076.
118. Sparano JAWM, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge
GW Jr, Wood WC, Davidson NE: Weekly paclitaxel in the adjuvant
treatment of breast cancer. N Engl J Med 2008, 358(16):1663–1671.
119. Tallman MSRG, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP,
Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM: Conventional
Adjuvant Chemotherapy with or without High-Dose Chemotherapy and
Autologous Stem-Cell Transplantation in High-Risk Breast Cancer.
N Engl J Med 2003, 349(1):17–26.
120. Tominaga T, Toi M, Abe O, Ohashi Y, Uchino J, Hayasaka H, Abe R, Izuo M,
Enomoto K, Watanabe H, Yoshida M, Taguchi T, Koyama H, Senoo T, Toge T,
Monden Y, Hattori T, Nomura Y, Sugimachi K, Hirata K, Nakazato H, Miura S,
Morimoto T, Asaishi K, Kimijima I, Ota J, Sonoo H, Yamaguchi S, 5′-BC Study
Group (5′-DFUR Adjuvant Chemotherapy for Breast Cancer Study Group):
The effect of adjuvant 5′-deoxy-5-fluorouridine in early stage breast
cancer patients: results from a multicenter randomized controlled trial.
Int J Oncol 2002, 20(3):517–525.
121. Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno
N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G,
Ohashi Y: Oral Uracil and Tegafur Compared With Classic
Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative
Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer:
National Surgical Adjuvant Study for Breast Cancer 01 Trial. J Clin Oncol
2009, 27(9):1368–1374.
122. Sirohi B, A’Hern R, Coombes G, Bliss JM, Hickish T, Perren T, Crawford M,
O’Brien M, Iveson T, Ebbs S, Skene A, Laing R, Smith IE: A randomised
comparative trial of infusional ECisF versus conventional FEC as adjuvant
chemotherapy in early breast cancer: the TRAFIC trial. Ann Oncol 2010,
21(8):1623–1629.
Sperduti et al. Journal of Experimental & Clinical Cancer Research 2013, 32:89 Page 12 of 12
http://www.jeccr.com/content/32/1/89123. Tada K, Yoshimoto M, Nishimura S, Takahashi K, Makita M, Iwase T,
Takahashi S, Ito Y, Hatake K, Ueno M, Nakagawa K, Kasumi F: Comparison of
two-year and five-year tamoxifen use in Japanese post-menopausal
women. Eur J Surg Oncol 2004, 30(10):1077–1083.
124. Adjuvant Breast Cancer Trials Collaborative Group: Polychemotherapy for
early breast cancer: results from the international adjuvant breast cancer
chemotherapy randomized trial. J Natl Cancer Inst 2007, 99(7):506–515.
125. Adjuvant Breast Cancer Trials Collaborative Group: Ovarian ablation or
suppression in premenopausal early breast cancer: results from the
international adjuvant breast cancer ovarian ablation or suppression
randomized trial. J Natl Cancer Inst 2007, 99(7):516–525.
126. Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C,
Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J,
Diaz-Rubio E, GEICAM Group (Spanish Breast Cancer Research Group), Spain:
Doxorubicin in combination with fluorouracil and cyclophosphamide
(i.v. FAC regimen, day 1, 21) versus methotrexate in combination with
fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as
adjuvant chemotherapy for operable breast cancer: a study by the
GEICAM group. Ann Oncol 2003, 14(6):833–842.
127. Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW, Shapiro CL, Ingle
JN, Lew D, Hutchins LF, Livingston RB, Martino S: Sequenced Compared
With Simultaneous Anthracycline and Cyclophosphamide in High-Risk
Stage I and II Breast Cancer: Final Analysis From INT-0137 (S9313).
J Clin Oncol 2007, 25(6):656–661.
128. Recommended breast cancer surveillance guidelines: American Society of
Clinical Oncology. J Clin Oncol 1997, 15(5):2149–2156.
129. Oltra A, Santaballa A, Munarriz B, Pastor M, Montalar J: Cost-benefit analysis
of a follow-up program in patients with breast cancer: a randomized
prospective study. Breast J 2007, 13(6):571–574.
130. van Hezewijk M, van den Akker ME, van de Velde CJ, Scholten AN, Hille ET:
Costs of different follow-up strategies in early breast cancer: a review of
the literature. Breast 2012, 21(6):693–700.
131. Kokko R, Hakama M, Holli K: Follow-up cost of breast cancer patients with
localized disease after primary treatment: a randomized trial. Breast
Cancer Res Treat 2005, 93(3):255–260.
132. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A,
Winer EP, Cardoso F: International Guidelines for Management of
Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? J Natl
Cancer Inst 2010, 102(7):456–463.
133. Ogawa Y, Ikeda K, Izumi T, Okuma S, Ichiki M, Ikeya T, Morimoto J,
Nishiguchi Y, Ikehara T: First indicators of relapse in breast cancer:
evaluation of the follow-up program at our hospital. Int J Clin Oncol 2012,
18(3):447–53.
134. Barni S, Venturini M, Molino A, Donadio M, Rizzoli S, Maiello E, Gori S:
Importance of adherence to guidelines in breast cancer clinical practice.
The Italian experience (AIOM). Tumori 2011, 97(5):559–563.
135. Donnelly P, Hiller L, Bathers S, Bowden S, Coleman R: Questioning
specialists’ attitudes to breast cancer follow-up in primary care.
Ann Oncol 2007, 18(9):1467–1476.
136. Montgomery DA, Krupa K, Cooke TG: Alternative methods of follow up in
breast cancer: a systematic review of the literature. Br J Cancer 2007,
96(11):1625–1632.
137. Geurts SM, De Vegt F, Siesling S, Flobbe K, Aben KK, Van Der Heiden Van
Der Loo M, Verbeek AL, Van Dijck JA, Tjan Heijnen VC: Pattern of follow-up
care and early relapse detection in breast cancer patients. Breast Cancer
Res Treat 2012, 136(3):859–868.
138. Dewar JA, Kerr GR: Value of routine follow up of women treated for early
carcinoma of the breast. Br Med J (Clin Res Ed) 1985, 291(6507):1464–1467.
139. Pandya KJ, McFadden ET, Kalish LA, Tormey DC, Taylor SG, Falkson G: A
retrospective study of earliest indicators of recurrence in patients on
Eastern Cooperative Oncology Group adjuvant chemotherapy trials for
breast cancer. A preliminary report. Cancer 1985, 55(1):202–205.
140. Schapira DV, Urban N: A minimalist policy for breast cancer surveillance.
JAMA 1991, 265(3):380–382.
141. Zwaveling A, Albers GH, Felthuis W, Hermans J: An evaluation of routine
follow-up for detection of breast cancer recurrences. J Surg Oncol 1987,
34(3):194–197.142. Smith TJ, Davidson NE, Schapira DV, Grunfeld E, Muss HB, Vogel VG 3rd,
Somerfield MR: American Society of Clinical Oncology 1998 update of
recommended breast cancer surveillance guidelines. J Clin Oncol 1999,
17(3):1080–1082.
143. Bonomi M, Pilotto S, Milella M, Massari F, Cingarlini S, Brunelli M, Chilosi M,
Tortora G, Bria E: Adjuvant chemotherapy for resected non-small-cell lung
cancer: future perspectives for clinical research. J Exp Clin Cancer Res
2011, 30(1):115–123.
doi:10.1186/1756-9966-32-89
Cite this article as: Sperduti et al.: Breast cancer follow-up strategies in
randomized phase III adjuvant clinical trials: a systematic review. Journal
of Experimental & Clinical Cancer Research 2013 32:89.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
